Irritable Bowel Syndrome|Inhibitors Agonists Modulators Antagonists|HmoBio.com

Request The Product List ofIrritable Bowel Syndrome Irritable Bowel Syndrome

Irritable bowel syndrome (IBS) is a disorder that leads to pain in abdomen and bowel changes.

IBS is not the same as inflammatory bowel disease (IBD).

Causes

The reasons why IBS develops are not clear. It can occur after a bacterial infection or a parasitic infection (giardiasis) of the intestines. This is called postinfectious IBS. There may also be other triggers, including stress.

The intestine is connected to the brain using hormone and nerve signals that go back and forth between the bowel and the brain. These signals affect bowel function and symptoms. The nerves can become more active during stress. This can cause the intestines to be more sensitive and contract more.

IBS can occur at any age. Often, it begins in the teen years or early adulthood. It is twice as common in women as in men.

It is less likely to begin in older people above 50 years of age.

Cat. No.	Product Name	CAS No.	Information
H3228	Pexacerfont	459856-18-9	Pexacerfont is a potent, selective and orally active CRF1 receptor antagonist with IC50 of 6.1 nM, >1,000-fold selectivity over CRF-binding protein and biogenic amine receptors; demonstrates oral effectivity in rat models of anxiety, possesses good pharmacokinetic profile in vivo.
H8815	Dapiglutide	2296814-85-0	Dapiglutide is a potent GLP-1/GLP-2 receptor agonist.
H7964	GSK3179106	1627856-64-7	GSK3179106 (GSK-3179106, GSK 3179106) is a potent, selective, first-in-class and gut-restricted RET kinase inhibitor with IC50 of 0.4 and 11 nM in the biochemical assay and cellular assay respectively, 273-fold selectivity over KDR; possesses good kinase selectivity, only 26 out of a set of >300 recombinant kinases were found to be inhibited at 1 uM; GSK3179106 dosed orally at 10 mg/kg for 3.5 days BID reduced the visceromotor response to colorectal distension in comparison to rats given an acetic acid enema and dosed with vehicle, GSK3179106 has been developed for the treatment of IBS in a clinical setting.
H6888	ONO-2952	895169-20-7	A novel potent, selective, orally active translocator protein 18 kDa (TSPO/PBR) antagonist with Ki of 0.33-9.3 nM for both rat and human TSPO; displays high selectivity over 98 other receptors, transporters, ion channels and enzymes; inhibits both neurosteroid accumulation and noradrenaline release in the brain of rats exposed to acute stress; suppresses conditioned fear stress-induced freezing behavior in rats with an efficacy equivalent to that of diazepam, but without not affect learning and memory.
H6676	SC 57461	423169-68-0	A potent and selective inhibitor of LTA4 hydrolase (LTA4H) with IC50/Ki of 5 nM/23 nM; inhibits calcium ionophore-induced LTB(4) production in human whole blood (IC50=49 nM), no effect on production of the cyclooxygenase metabolite thromboxane B(2); orally active in vivo.
H5585	LX-1031	945976-76-1	LX-1031 is a potent, orally active tryptophan 5-hydroxylase (TPH) inhibitor with potency of 10-100 nM, reduces 5-HT synthesis peripherally; dose-dependently reduces expression of 5-HT in the duodenum, jejunum and ileum, but had no effect on brain 5-HT levels, significantly reduces urinary 5-hydroxyindoleacetic acid (5-HIAA) in vivo; exhibits potential for illnesses characterized by excess 5-HT, such as diarrhea-predominant irritable bowel syndrome (IBS-D) and carcinoid diarrhea.
H5175	Linaclotide	851199-59-2	A potent and selective GC-C agonist (Ki=1.23-1.64 nM) that elicits pharmacological effects locally in the gastrointestinal tract; induces a significant increase in fluid secretion, accompanied by a significant increase in intraluminal cGMP levels; has potential for the treatment of constipation-predominant irritable bowel syndrome (IBS-C) and chronic constipation.
H4127	Semapimod hydrochloride	164301-51-3	Semapimod (CNI 1493;AXD-455) is a tetravalent guanylhydrazone that acts as a selective inhibitor of cytokine-inducible arginine transport and NO production, inhibits TLR4 signaling (IC50=0.3 uM) by targeting the TLR chaperone gp96; does not inhibit EDRF activity, inhibits nitric oxide synthesis by inflammatory macrophages; prevents the development of carrageenan-induced footpad inflammation, and conferred protection against lethal LPS challenge in mice.
H4126	Semapimod	352513-83-8	Semapimod (CNI 1493;AXD-455) is a tetravalent guanylhydrazone that acts as a selective inhibitor of cytokine-inducible arginine transport and NO production, inhibits TLR4 signaling (IC50=0.3 uM) by targeting the TLR chaperone gp96; does not inhibit EDRF activity, inhibits nitric oxide synthesis by inflammatory macrophages; prevents the development of carrageenan-induced footpad inflammation, and conferred protection against lethal LPS challenge in mice.
H3696	Eluxadoline	864821-90-9	A potent, selective, orally bioavailable µ-opioid receptor agonist and a δ-opioid receptor antagonist for the treatment of diarrhoea-predominant irritable bowel syndrome (IBS-D).

Select Your Country or Region

Request The Product List ofIrritable Bowel Syndrome Irritable Bowel Syndrome

Request The Product List

* Indicates a Required FieldYour information is safe with us.